{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:03:48Z","timestamp":1787166228999,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1245\/s10434-019-08038-8","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T13:02:51Z","timestamp":1573822971000},"page":"743-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"27","author":[{"given":"Nicole","family":"Christian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"8038_CR1","doi-asserted-by":"crossref","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;18(2):Cd005002.","DOI":"10.1002\/14651858.CD005002.pub2"},{"issue":"5","key":"8038_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778\u201385.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8038_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137\u201346.","journal-title":"Lancet Oncol"},{"issue":"16","key":"8038_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","volume":"30","author":"V Guarneri","year":"2012","unstructured":"Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989-95.","journal-title":"J Clin Oncol"},{"key":"8038_CR5","doi-asserted-by":"crossref","unstructured":"Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434\u20139; discussion 8\u20139.","DOI":"10.1097\/SLA.0000000000001417"},{"issue":"2","key":"8038_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-016-4006-6","volume":"160","author":"M Golshan","year":"2016","unstructured":"Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat 2016;160(2):297\u2013304.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8038_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1245\/s10434-017-6217-4","volume":"25","author":"O Kantor","year":"2018","unstructured":"7. Kantor O, Ajmani G, Wang CH, Datta A, Yao K. The shifting paradigm for breast cancer surgery in patients undergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(1):164\u201372.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"8038_CR8","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1002\/ijc.31747","volume":"143","author":"EL Pollom","year":"2018","unstructured":"Pollom EL, Qian Y, Chin AL, et al. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. Int J Cancer. 2018;143(12):3262\u201372.","journal-title":"Int J Cancer"},{"issue":"2","key":"8038_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/SLA.0000000000001972","volume":"266","author":"IL Wapnir","year":"2017","unstructured":"Wapnir IL, Kurian AW, Lichtensztajn DY, Clarke CA, Gomez SL. Rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California from 1998 to 2012. Ann Surg. 2017;266(2):353\u201360.","journal-title":"Ann Surg"},{"issue":"3","key":"8038_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 2017;265(3):581\u20139.","journal-title":"Ann Surg"},{"issue":"2","key":"8038_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","volume":"24","author":"KK Hunt","year":"2017","unstructured":"Hunt KK, Euhus DM, Boughey JC, et al. Society of Surgical Oncology Breast Disease Working Group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol. 2017;24(2):375\u201397.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"8038_CR12","doi-asserted-by":"publisher","first-page":"dju160","DOI":"10.1093\/jnci\/dju160","volume":"106","author":"P. R. Portschy","year":"2014","unstructured":"Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst. 2014;106(8).","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"33","key":"8038_CR13","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"8038_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1200\/JCO.2008.20.1681","volume":"27","author":"TM Tuttle","year":"2009","unstructured":"Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8038_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"8038_CR16","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","volume":"29","author":"TA King","year":"2011","unstructured":"King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158\u201364.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8038_CR17","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","volume":"14","author":"T Saphner","year":"1996","unstructured":"Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738\u201346.","journal-title":"J Clin Oncol"},{"issue":"13","key":"8038_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"7","author":"NN Basu","year":"2015","unstructured":"Basu NN, Ross GL, Evans DG, Barr L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J Surg Oncol. 2015;13:237.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"8038_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jnci\/djq018","volume":"102","author":"I Bedrosian","year":"2010","unstructured":"Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8038_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9610(00)00505-5","volume":"180","author":"EA Peralta","year":"2000","unstructured":"Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000;180(6):439\u201345.","journal-title":"Am J Surg"},{"issue":"3","key":"8038_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamasurg.2016.4749","volume":"152","author":"R Jagsi","year":"2017","unstructured":"Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg 2017;152(3):274\u201382.","journal-title":"JAMA Surg"},{"issue":"15","key":"8038_CR22","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544\u201352.","journal-title":"Cancer"},{"issue":"12","key":"8038_CR23","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1245\/s10434-017-6016-y","volume":"24","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M. The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol. 2017;24(12):3527\u201333.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"8038_CR24","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"8038_CR25","first-page":"391","volume":"265","author":"National Institutes of Health","year":"1991","unstructured":"25. National Institutes of Health. NIH consensus conference. Treatment of early-stage breast cancer. Jama 1991;265(3):391\u20135.","journal-title":"Treatment of early-stage breast cancer. Jama"},{"issue":"4","key":"8038_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/tbj.12977","volume":"24","author":"MR Cassidy","year":"2018","unstructured":"Cassidy MR, Zabor EC, Stempel M, Mehrara B, Gemignani ML. Does response to neo-adjuvant chemotherapy impact breast reconstruction? Breast J. 2018;24(4):567\u201373.","journal-title":"Breast J"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-08038-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T19:05:38Z","timestamp":1605294338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-08038-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["8038"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-08038-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this manuscript was funded in part by NIH\/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center, Dr. Monica Morrow has received speaking honoraria from Genomic Health and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}